FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a method for production of egg yolk with a very high content of antisecretory factor (AF) proteins and products based thereon. Egg yolk for treating and preventing diarrhea and dehydration, containing at least 0.05 ng/ml of an antisecretory factor (AF) protein fragment with an amino acid sequence disclosed in SEQ.ID.NO.1 and/or SEQ.ID.NO.2. Yolk fodder food. Method of egg yolk production. Egg yolk for treating and preventing diarrhea and dehydration, obtained by the method described above. Application of egg yolk during treatment and/or prevention of painful conditions, caused by one of selected from group consisting of extreme release of body fluids, discomfort due to physiological imbalance, inflammation, edema, arthritis, glaucoma, migraine, burns and/or traumatic injuries in and on the body. Egg yolk application in treating diarrhea and/or dehydration. Application of egg yolk during treatment and/or prevention of any one of diseases selected from a group consisting of inflammatory diseases, malignant neoplasm, glioblastoma, intraocular hypertension, compartment syndrome, Parkinson's disease, Alzheimer's disease and diabetes. Application of egg yolk during neuroprotection. Application of egg yolk with optimization of delivery and/or cellular absorption of pharmaceutical substance and/or dosage form, such as a malignant neoplasm. Application of egg yolk in immunotherapy. Egg yolk application in radiation therapy or gene delivery to a tumor cell. Egg yolk application improves nerve tissue repair. Application of egg yolk with improvement of proliferation of stem cells and precursor cells. Application of egg yolk with improvement of apoptosis of stem cells and precursor cells. Application of egg yolk with improvement of differentiation of stem cells and precursor cells. Application of egg yolk with improved migration of stem cells and precursor cells and cell derivatives. Application of egg yolk for production of enriched with antioxidant factor (AF) fodder, food and/or food additives. Food containing egg yolk. Egg yolk containing fodder. Food additive containing egg yolk. Pharmaceutical composition for treating and preventing diarrhea and dehydration containing egg yolk, suitable pharmaceutical carrier. Application of egg yolk for preparing a drug for treating and/or preventing painful conditions caused by extreme release of body fluids, discomfort due to physiological imbalance, inflammations, edema, arthritis, glaucoma, migraine, burns and/or traumatic injuries in and on the body, in treating diarrhea and/or dehydration, when treating and/or preventing any one of diseases selected from the group consisting of inflammatory diseases, malignant growths, glioblastoma, intraocular hypertension, compartment syndrome, Parkinson's disease, Alzheimer's disease and diabetes. Application of egg yolk for producing a drug specified in a drug for neuroprotection, optimizing the delivery and/or cellular absorption of the pharmaceutical substance and/or dosage form, such as a malignant drug, immunotherapy, radiation therapy or gene delivery to a tumor cell, improved repair of nerve tissue, improved proliferation of stem cells and precursor cells, improved apoptosis of stem cells and precursor cells, improved differentiation of stem cells and precursor cells, improved migration of stem cells and precursor cells and cell derivatives. Method for treatment and/or prevention of disease states caused by one of selected from a group consisting of extreme release of body fluids, discomfort due to physiological imbalance, inflammation, edema, arthritis, glaucoma, migraine, burns and/or traumatic injuries in and on the body, for treating diarrhea and/or dehydration, for treating and/or preventing any one of diseases selected from the group consisting of inflammatory diseases, malignant growths, glioblastoma, intraocular hypertension, compartment syndrome, Parkinson's disease, Alzheimer's disease and diabetes, wherein the method involves administering a pharmaceutically effective amount of egg yolk to a subject in need thereof.
EFFECT: yolk described above is characterized by high content of antisecretory factor (AF) proteins, effective for treating various diseases and conditions.
36 cl, 3 dwg, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
NUCLEIC ACID CONSTRUCTIONS AND VECTORS FOR GENOTHERAPY FOR TREATING WILSON'S DISEASE AND OTHER CONDITIONS | 2015 |
|
RU2745567C2 |
COMPOSITION CONTAINING PROBIOTICS AND POLYPEPTIDE HAVING BINDING AFFINITY RELATIVELY TO IgE AND ITS USE | 2019 |
|
RU2786578C2 |
METHOD OF PRODUCING FOOD ADDITIVE FROM ALCOHOL-SOLUBLE FRACTION OF EGG YOLK | 2022 |
|
RU2815743C1 |
ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
NPP1 FUSION PROTEINS | 2011 |
|
RU2760943C2 |
PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II | 2016 |
|
RU2742612C2 |
Authors
Dates
2020-06-08—Published
2016-06-20—Filed